Dimerix Ltd News

Dimerix Initiated at Buy by Petra Capital

Dimerix Initiated at Buy by Petra Capital

Dow JonesMay 30 23:29

Euroz Hartleys Adjusts Dimerix's Price Target to AU$0.86 From AU$0.80, Keeps at Speculative Buy

12:54 AM EDT, 05/29/2024 (MT Newswires) -- Euroz Hartleys Adjusts Dimerix's Price Target to AU$0.86 From AU$0.80, Keeps at Speculative Buy Price (AUD): $0.40, Change: $+0.01, Percent Change: +2.56%

MT NewswiresMay 28 23:54

Dimerix's Middle East Licensing Deal Signals More Agreements to Come -- Market Talk

1840 ET - Dimerix's licensing deal with UAE-based pharmaceutical group Taiba for its DMX-200 treatment of focal segmental glomerulosclerosis, a rare kidney disease, in the Middle East is a positive su

WSJMay 28 17:40

Dimerix Price Target Raised 7.5% to A$0.86/Share by Euroz Hartleys

Dimerix Price Target Raised 7.5% to A$0.86/Share by Euroz Hartleys

Dow JonesMay 28 17:06

Dimerix Signs License Deal for Kidney Disease Medication in the Middle East

Dimerix (ASX:DXB) signed an exclusive license deal with private medicine supplier Taiba Middle East to commercialize the kidney disease medicinal candidate DMX-200 in the Middle East, according to a M

MT NewswiresMay 27 02:47

Dimerix (ASX:DXB) Shareholders Have Earned a 359% Return Over the Last Year

Yahoo FinanceMay 23 17:29

Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication

Dimerix (ASX:DXB) secured approval from the UK Medicines and Healthcare Products Regulatory Agency for the pediatric investigation plan for its kidney disease medication DMX-200, according to a Wednes

MT NewswiresApr 30 19:57

Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter

Dimerix (ASX:DXB) has reported AU$35.2 million in cash and AU$3.3 million of operating cash outflows for the quarter ended March 31, mostly from clinical and CMC costs related to its Phase 3 FSGS stud

MT NewswiresApr 22 16:29

Dimerix Initiated at A$0.80/Share Price Target by Euroz Hartleys

Dimerix Initiated at A$0.80/Share Price Target by Euroz Hartleys

Dow JonesApr 18 21:59

Dimerix With Proactive at ASX Small and Mid Cap Conference | ASX:DXB, OTC:SBMJF

Proactive InvestorsMar 27 06:45

Dimerix Raises AU$20 Million for Kidney Disease Study

Dimerix (ASX:DXB) raised AU$20 million via an institutional placement of 66,666,667 ordinary shares at AU$0.30 apiece. Proceeds will be used to complete the ACTION3 phase three clinical study in patie

MT NewswiresMar 12 03:37

Dimerix Expanding Kidney Drug Study After DMX-200 Performs Better Than Placebo

Dimerix (ASX:DXB) said it will expand its kidney drug study after DMX-200 performed better than the placebo in reducing proteinuria. Phase three trial achieved success in its pre-specified interim ana

MT NewswiresMar 10 21:40

Calculating The Intrinsic Value Of Dimerix Limited (ASX:DXB)

Yahoo FinanceFeb 27 17:48

Dimerix Secures Investigational New Drug Approval for Kidney Disease Medication in China; Shares Rally 11%

Dimerix (ASX:DXB) secured an investigational new drug approval for the DMX-200 medication from the Chinese National Medical Products Administration's Center for Drug Evaluation, according to a Tuesday

MT NewswiresNov 27, 2023 20:27

Dimerix Appoints Nonexecutive Chair

Biopharmaceutical company Dimerix (ASX:DXB) appointed Mark Diamond as nonexecutive chair, effective Dec. 1. In May, Diamond retired from Antisense Therapeutics (ASX:ANP) as managing director and chief

MT NewswiresNov 19, 2023 21:10

Shareholders Will Likely Find Dimerix Limited's (ASX:DXB) CEO Compensation Acceptable

Yahoo FinanceNov 14, 2023 14:35

Dimerix Receives AU$10.7 Million Upfront Payment for Commercialization Rights

Dimerix (ASX:DXB) received the initial upfront payment of AU$10.7 million from Advanz Pharma for the exclusive rights to commercialize DMX-200 in the European Economic Area, the UK, Switzerland, Canad

MT NewswiresNov 7, 2023 01:39

Dimerix Appoints Medical Chief

Dimerix (ASX:DXB) appointed David Fuller as chief medical officer, succeeding Ash Soman. Fuller is the chair of diagnostic company EpiAxis Therapeutics and nonexecutive director of biotech company, Ad

MT NewswiresOct 22, 2023 22:50

Softer US Employment Data End Australian Shares' Three-Day Losing Streak

Australian shares ended their three-day losing streak, rebounding on Thursday as concerns over the US Federal Reserve hiking rates further eased amid softer US employment data. The S&P/ASX 200 Index r

MT NewswiresOct 5, 2023 02:34

Dimerix Surges 154% After Securing License Deal for Kidney Disease Drug

Dimerix (ASX:DXB) shares surged 154% in recent trade after the company secured a licensing deal for its kidney disease drug. The company entered into an exclusive license agreement with Advanz Pharma

MT NewswiresOct 5, 2023 00:02